Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The previous studies investigated the scaffold as mechanical carrier to stem cells or growth factors as transplantation therapy. This study aimed to investigate the effect of nanofiber scaffold on immunomodulatory properties of MSCs in osteoarthritis (OA) and the mechanism of this effect.
Methods: Collagen coated PCL nanofiber was prepared and examined by SEM. Mononuclear cells (MNCs) from the peripheral blood (P.B) and synovial fluid (SF) cultured with BMMSCs after stimulation by PHA using two types of co-culture (MSCs/Nano and MSCs/nano). Using flowcytometry, CD4, CD8, CD28, activation markers CD38 and CD23, regulatory CD4CD25 foxp3, CD14, IL17 by ELISA and cell proliferation using CCK-8 were assessed. ICAM mRNA was assessed by qRT-PCR and flowcytometry.
Results: MSCs/nano showed more significant inhibitory effect of MSCs regarding CD4, CD8, CD28, CD28 MFI, CD38, CD38 MFI, CD23, CD23 MFI, CD14, IL17 (p < 0.001) and higher level of Treg cells (p < 0.001) than nano with difference regarding cell proliferation (p = 0.275). Also, the immunomodulatory effect of MSCs culture on nano on lymphocyte separated from S·F of osteoarthritis patients more powerful than nano. The secretory function of MSCs culture on nano is more beneficial than that of nano Nano showed higher level of ICAM mRNA and CD54 than nano.
Conclusion: The present study proved a novel function of nanofiber by increasing the immunomodulatory effect of the MSCs in osteoarthritis through increased the ICAM expression and this promising for increase the success of MSCs transplantation in OA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.trim.2022.101625 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The use of injectable orthobiologics for knee osteoarthritis: A formal ESSKA-ORBIT consensus. Part 2-Cell-based therapy.
Knee Surg Sports Traumatol Arthrosc
September 2025
Department of Orthopaedics, Hillel Yaffe Medical Center (HYMC), Hadera, Clinic, Tel-Aviv, Israel.
Purpose: This European Society of Sports Traumatology, Knee Surgery and Arthroscopy (ESSKA) formal consensus aims to provide evidence- and expert opinion-based recommendations for the use of point-of-care- and expanded-cell-based therapy (CBT) in the treatment of knee osteoarthritis (OA), focusing on indications, preparation, and administration.
Methods: A multidisciplinary group of 77 leading experts in musculoskeletal regenerative medicine from 22 European Countries formed a steering group, a rating group, and a reader group. The steering group developed 23 questions, originating from 27 statements.
Human Umbilical Cord Mesenchymal Stem Cells Inhibit the Progression of Osteoarthritis by Suppressing NLRP3-Mediated Synovial Inflammation in the Early Stages of the Disease.
Stem Cells Int
August 2025
R&D Center, Wuhan Hamilton Biotechnology Co. Ltd, Wuhan, Hubei, China.
Osteoarthritis (OA) is the leading joint disease that causes joint pain and disability. Despite increasing progress regarding the therapeutic potential of human umbilical cord mesenchymal stem cells (UC-MSCs) for OA, effective strategies for the treatment of OA using UC-MSCs have not yet been developed in clinical practice. Our present study has proven that the early stage in OA rats is the main development stage of nod-like receptor heat protein domain protein 3 (NLRP3)-mediated synovial inflammation.
View Article and Find Full Text PDFIdentification of critical process parameters and quality attributes for bioreactor-based expansion of human MSCs.
Front Bioeng Biotechnol
August 2025
Department Bio-Adaptive production, Fraunhofer Institute for Production Technology (FHG), Aachen, Germany.
Mesenchymal stem/stromal cells (MSCs) have been identified as a promising therapeutic option for osteoarthritis, graft vs. host disease and cardiovascular diseases, among others. For widespread application of these therapies, robust and scaled manufacturing processes are required that reliably yield high amounts of high quality MSCs.
View Article and Find Full Text PDFImmunoregulatory orchestrations in osteoarthritis and mesenchymal stromal cells for therapy.
J Orthop Translat
November 2025
Key Laboratory of Tropical Translational Medicine of Ministry of Education & Key Laboratory of Brain Science Research and Transformation in Tropical Environment of Hainan Province, Hainan Provincial Stem Cell Research Institute, School of Basic Medicine and Life Sciences, Hainan Medical University,
Unlabelled: Osteoarthritis (OA) is characterized by the inability of stable and complex joint structures to function as they did, accompanied by inflammation, tissue changes, chronic pain, and neuropathic inflammation. In the past, the primary focus on the causes of joint dysfunction has been on mechanical stress leading to cartilage wear. Further researches emphasize the aging of cartilage and subchondral bone triggered cartilage lesion and osteophyte formation.
View Article and Find Full Text PDFVeterinary Regenerative Medicine: The Evolving Role of Stem Cell-Based Therapies.
Stem Cell Rev Rep
September 2025
DBT-National Institute of Animal Biotechnology (NIAB), Hyderabad, 500032, Telangana, India.
Veterinary medicine has witnessed a paradigm shift in recent past with the preference to use mesenchymal stem cells (MSCs) for livestock and companion animal therapeutics. MSCs made remarkable developments in treating complex clinical conditions, otherwise difficult to treat with routine medications such as musculoskeletal injuries, osteoarthritis, tendon and ligament damage, degenerative diseases, gastritis, endometritis, diabetes mellitus, and ocular diseases, offering new hope for veterinary practitioners and animal caregivers. This review is divided into two sections: The first part explores recent advancements in veterinary medicine using MSCs, mainly focusing on their sources, administration methods, therapeutic mechanisms, and clinical applications.
View Article and Find Full Text PDF